Kit for EGFR gene mutation detection and application

Abstract

The invention discloses a kit for EGFR gene mutation detection and application, and belongs to the fields of biotechnology and medicine. Compared with the prior art, the kit has the advantages that aprimer, a probe and the kit of an amplification system are high in detection sensitivity, and can detect specimens with the mutation content being smaller than 0.1 percent; the detection accuracy is high, a double control detection system and a locked nucleic acid technology are adopted, and the reliability of detection results is guaranteed; only 8 reactions are needed, including EGFR quality control reaction liquid, L858R detection reaction liquid, 19del detection reaction liquid, G719X detection reaction liquid, L861Q detection reaction liquid, 3Ins20 detection reaction liquid, T790M detection reaction liquid and S768I detection reaction liquid, to be used for detecting 29 common mutant types of EGFR gene in serum or plasma and tissue samples of non-small cell lung cancer patients.

Description

Technical field [0001] The present invention relates to the fields of biotechnology and medicine, and in particular to a kit for EGFR gene mutation detection and its application, including a kit for EGFR gene mutation detection and its primers, probes and amplification systems. Background technique [0002] At present, lung cancer has become the leading cause of cancer deaths in the world, with 1.5 million new cases each year, a serious threat to human health. Among lung cancer patients, non-small cell lung cancer (NSCLC) accounts for about 80%, and 80% have lost the best chance of surgery or radiotherapy at the time of treatment, resulting in a low long-term survival rate and worrying efficacy. The 2-year survival rate of stage IIIB / IV non-small cell lung cancer is only 10%-20%, and the median survival time is only 10-12 months. Therefore, people need to continue to study new treatment methods to improve the effective treatment of lung cancer. Among them, new treatment methods ...

AI Technical Summary

Problems solved by technology

The sequencing method is about 20% less sensitive, and the operation is complicated, the detection time is longer, and the false negative rate is higher

The ARMS-PCR method can achieve a sensitivity of 1%, which can meet the detection requirements for tumor tissue samples, but for blood samples that are convenient to sample, such as circulating tumor cells in plasma or blood, the tumor DNA content is often lower than 1%, ARMS-PCR The sensitivity of the method is not enough to detect the blood, which limits the judgment of clinicians on the efficacy of targeted drugs

In addition, drug resistance mutations may occur during clinical drug use, and previous methods cannot be detected due to insufficient sensitivity

Images